FDA Approved: ZYTIGA — Original Application (Janssen Biotech, Inc.)

View source ↗

Summary

FDA approves ZYTIGA (abiraterone acetate) under NDA 202379, marking the original approval for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

ORIG AP for ZYTIGA (ABIRATERONE ACETATE)